A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza a Infection
Four hundred fifty volunteers participated in a placebo-controlled, double-blind, randomized trial of the prophylactic effects of rimantadine and amantadine during an outbreak of influenza A. The subjects received drugs orally at a dose of 100 mg twice a day for six weeks. Influenza-like illness occ...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1982-09, Vol.307 (10), p.580-584 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 584 |
|---|---|
| container_issue | 10 |
| container_start_page | 580 |
| container_title | The New England journal of medicine |
| container_volume | 307 |
| creator | Dolin, Raphael Reichman, Richard C Madore, H. Paul Maynard, Raina Linton, Pamela N Webber-Jones, Joan |
| description | Four hundred fifty volunteers participated in a placebo-controlled, double-blind, randomized trial of the prophylactic effects of rimantadine and amantadine during an outbreak of influenza A. The subjects received drugs orally at a dose of 100 mg twice a day for six weeks.
Influenza-like illness occurred in 41 per cent of the subjects receiving placebo but in only 14 per cent of those receiving rimantadine and 9 per cent of those receiving amantadine (P |
| doi_str_mv | 10.1056/NEJM198209023071002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15501400</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15501400</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-3185205b2697e04044f096a2a77067648b002e48d96f34e8060a9c9196b3c4ee3</originalsourceid><addsrcrecordid>eNp9UF1r2zAUFWOjS9P9gjIQDPZSvF59WLIeQ8jajPSD0r4NjGJfUwdbyiQb2v76KiSsMMruy_0653DvIeSUwQ8GuTq_Xvy6YqbgYIAL0AyAfyATlguRSQnqI5mkSZFJbcRnchzjBlIwaY7IkYYcNPAJ-T2jc--G4LsOa3ofWttR39BZb91g69Yhta6md-1b3zo6PCK9DX77-NzZpzbuCEvXdCO6F0vtrsZqaL07IZ8a20X8cshT8vBzcT-_zFY3F8v5bJVV0pghE6zIOeRrroxGkCBlA0ZZbrUGpZUs1ukPlEVtVCMkFqDAmsowo9aikohiSr7vdbfB_xkxDmXfxgq7zjr0YyxZnqe_ARLw2z_AjR-DS7eVrNCca11ollBij6qCjzFgU25DMiA8lwzKnfPlO84n1teD9rjusf7LOVid9mf7fd_H0uGm_6_aK6Bdh38</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1872277871</pqid></control><display><type>article</type><title>A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza a Infection</title><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><creator>Dolin, Raphael ; Reichman, Richard C ; Madore, H. Paul ; Maynard, Raina ; Linton, Pamela N ; Webber-Jones, Joan</creator><creatorcontrib>Dolin, Raphael ; Reichman, Richard C ; Madore, H. Paul ; Maynard, Raina ; Linton, Pamela N ; Webber-Jones, Joan</creatorcontrib><description>Four hundred fifty volunteers participated in a placebo-controlled, double-blind, randomized trial of the prophylactic effects of rimantadine and amantadine during an outbreak of influenza A. The subjects received drugs orally at a dose of 100 mg twice a day for six weeks.
Influenza-like illness occurred in 41 per cent of the subjects receiving placebo but in only 14 per cent of those receiving rimantadine and 9 per cent of those receiving amantadine (P<0.001 for either drug vs. placebo). Laboratory-documented influenza occurred in 21 per cent of placebo recipients, 3 per cent of rimantadine recipients, and 2 per cent of amantadine recipients (P<0.001). These findings represent efficacy rates of 85 per cent for rimantadine and 91 per cent for amantadine, as compared with placebo. More recipients of amantadine (13 per cent) than recipients of rimantadine (6 per cent; P<0.05) or placebo (4 per cent; P<0.01) withdrew from the study because of Central-nervous-system side effects. On the basis of this study, rimantadine appears to be the drug of choice for the prophylaxis of influenza A. (N Engl J Med. 1982; 307: 580–4.)
AMANTADINE hydrochloride (1-adamantanamine hydrochloride) was licensed in 1966 for the prophylaxis of infections with influenza A viruses of the H2N2 subtype, and it has subsequently been approved for the prophylaxis of infections with all influenza A subtypes. Despite accumulated evidence of the efficacy of amantadine in the prophylaxis of influenza in human beings,
1
2
3
4
5
6
the drug has received relatively little use for this purpose. In part, this has been a result of continued challenges to the evidence of its efficacy by some workers,
7
as well as concern over its reported side effects, which have varied considerably in frequency from study to . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM198209023071002</identifier><identifier>PMID: 7050702</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adamantane - analogs & derivatives ; Adolescent ; Adult ; Amantadine ; Amantadine - adverse effects ; Amantadine - therapeutic use ; Antimicrobial agents ; Antiviral drugs ; Chemotherapy ; Clinical Trials as Topic ; Disease prevention ; Enzymes ; Family medical history ; Health surveillance ; Humans ; Illnesses ; Immunoglobulins ; Infant, Newborn ; Infections ; Infectious diseases ; Influenza ; Influenza A ; influenza A virus ; Influenza A virus - isolation & purification ; Influenza, Human - epidemiology ; Influenza, Human - prevention & control ; Laboratory animals ; Middle Aged ; Outbreaks ; Patient Compliance ; Prophylaxis ; Random Allocation ; Respiratory diseases ; Rimantadine - adverse effects ; Rimantadine - therapeutic use ; Viruses ; Volunteers</subject><ispartof>The New England journal of medicine, 1982-09, Vol.307 (10), p.580-584</ispartof><rights>Copyright Massachusetts Medical Society Sep 2, 1982</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-3185205b2697e04044f096a2a77067648b002e48d96f34e8060a9c9196b3c4ee3</citedby><cites>FETCH-LOGICAL-c499t-3185205b2697e04044f096a2a77067648b002e48d96f34e8060a9c9196b3c4ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1872277871?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,64383,64385,64387,72239</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7050702$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dolin, Raphael</creatorcontrib><creatorcontrib>Reichman, Richard C</creatorcontrib><creatorcontrib>Madore, H. Paul</creatorcontrib><creatorcontrib>Maynard, Raina</creatorcontrib><creatorcontrib>Linton, Pamela N</creatorcontrib><creatorcontrib>Webber-Jones, Joan</creatorcontrib><title>A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza a Infection</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Four hundred fifty volunteers participated in a placebo-controlled, double-blind, randomized trial of the prophylactic effects of rimantadine and amantadine during an outbreak of influenza A. The subjects received drugs orally at a dose of 100 mg twice a day for six weeks.
Influenza-like illness occurred in 41 per cent of the subjects receiving placebo but in only 14 per cent of those receiving rimantadine and 9 per cent of those receiving amantadine (P<0.001 for either drug vs. placebo). Laboratory-documented influenza occurred in 21 per cent of placebo recipients, 3 per cent of rimantadine recipients, and 2 per cent of amantadine recipients (P<0.001). These findings represent efficacy rates of 85 per cent for rimantadine and 91 per cent for amantadine, as compared with placebo. More recipients of amantadine (13 per cent) than recipients of rimantadine (6 per cent; P<0.05) or placebo (4 per cent; P<0.01) withdrew from the study because of Central-nervous-system side effects. On the basis of this study, rimantadine appears to be the drug of choice for the prophylaxis of influenza A. (N Engl J Med. 1982; 307: 580–4.)
AMANTADINE hydrochloride (1-adamantanamine hydrochloride) was licensed in 1966 for the prophylaxis of infections with influenza A viruses of the H2N2 subtype, and it has subsequently been approved for the prophylaxis of infections with all influenza A subtypes. Despite accumulated evidence of the efficacy of amantadine in the prophylaxis of influenza in human beings,
1
2
3
4
5
6
the drug has received relatively little use for this purpose. In part, this has been a result of continued challenges to the evidence of its efficacy by some workers,
7
as well as concern over its reported side effects, which have varied considerably in frequency from study to . . .</description><subject>Adamantane - analogs & derivatives</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Amantadine</subject><subject>Amantadine - adverse effects</subject><subject>Amantadine - therapeutic use</subject><subject>Antimicrobial agents</subject><subject>Antiviral drugs</subject><subject>Chemotherapy</subject><subject>Clinical Trials as Topic</subject><subject>Disease prevention</subject><subject>Enzymes</subject><subject>Family medical history</subject><subject>Health surveillance</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Immunoglobulins</subject><subject>Infant, Newborn</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Influenza</subject><subject>Influenza A</subject><subject>influenza A virus</subject><subject>Influenza A virus - isolation & purification</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - prevention & control</subject><subject>Laboratory animals</subject><subject>Middle Aged</subject><subject>Outbreaks</subject><subject>Patient Compliance</subject><subject>Prophylaxis</subject><subject>Random Allocation</subject><subject>Respiratory diseases</subject><subject>Rimantadine - adverse effects</subject><subject>Rimantadine - therapeutic use</subject><subject>Viruses</subject><subject>Volunteers</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1982</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9UF1r2zAUFWOjS9P9gjIQDPZSvF59WLIeQ8jajPSD0r4NjGJfUwdbyiQb2v76KiSsMMruy_0653DvIeSUwQ8GuTq_Xvy6YqbgYIAL0AyAfyATlguRSQnqI5mkSZFJbcRnchzjBlIwaY7IkYYcNPAJ-T2jc--G4LsOa3ofWttR39BZb91g69Yhta6md-1b3zo6PCK9DX77-NzZpzbuCEvXdCO6F0vtrsZqaL07IZ8a20X8cshT8vBzcT-_zFY3F8v5bJVV0pghE6zIOeRrroxGkCBlA0ZZbrUGpZUs1ukPlEVtVCMkFqDAmsowo9aikohiSr7vdbfB_xkxDmXfxgq7zjr0YyxZnqe_ARLw2z_AjR-DS7eVrNCca11ollBij6qCjzFgU25DMiA8lwzKnfPlO84n1teD9rjusf7LOVid9mf7fd_H0uGm_6_aK6Bdh38</recordid><startdate>19820902</startdate><enddate>19820902</enddate><creator>Dolin, Raphael</creator><creator>Reichman, Richard C</creator><creator>Madore, H. Paul</creator><creator>Maynard, Raina</creator><creator>Linton, Pamela N</creator><creator>Webber-Jones, Joan</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>19820902</creationdate><title>A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza a Infection</title><author>Dolin, Raphael ; Reichman, Richard C ; Madore, H. Paul ; Maynard, Raina ; Linton, Pamela N ; Webber-Jones, Joan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-3185205b2697e04044f096a2a77067648b002e48d96f34e8060a9c9196b3c4ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1982</creationdate><topic>Adamantane - analogs & derivatives</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Amantadine</topic><topic>Amantadine - adverse effects</topic><topic>Amantadine - therapeutic use</topic><topic>Antimicrobial agents</topic><topic>Antiviral drugs</topic><topic>Chemotherapy</topic><topic>Clinical Trials as Topic</topic><topic>Disease prevention</topic><topic>Enzymes</topic><topic>Family medical history</topic><topic>Health surveillance</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Immunoglobulins</topic><topic>Infant, Newborn</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Influenza</topic><topic>Influenza A</topic><topic>influenza A virus</topic><topic>Influenza A virus - isolation & purification</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - prevention & control</topic><topic>Laboratory animals</topic><topic>Middle Aged</topic><topic>Outbreaks</topic><topic>Patient Compliance</topic><topic>Prophylaxis</topic><topic>Random Allocation</topic><topic>Respiratory diseases</topic><topic>Rimantadine - adverse effects</topic><topic>Rimantadine - therapeutic use</topic><topic>Viruses</topic><topic>Volunteers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dolin, Raphael</creatorcontrib><creatorcontrib>Reichman, Richard C</creatorcontrib><creatorcontrib>Madore, H. Paul</creatorcontrib><creatorcontrib>Maynard, Raina</creatorcontrib><creatorcontrib>Linton, Pamela N</creatorcontrib><creatorcontrib>Webber-Jones, Joan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dolin, Raphael</au><au>Reichman, Richard C</au><au>Madore, H. Paul</au><au>Maynard, Raina</au><au>Linton, Pamela N</au><au>Webber-Jones, Joan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza a Infection</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1982-09-02</date><risdate>1982</risdate><volume>307</volume><issue>10</issue><spage>580</spage><epage>584</epage><pages>580-584</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Four hundred fifty volunteers participated in a placebo-controlled, double-blind, randomized trial of the prophylactic effects of rimantadine and amantadine during an outbreak of influenza A. The subjects received drugs orally at a dose of 100 mg twice a day for six weeks.
Influenza-like illness occurred in 41 per cent of the subjects receiving placebo but in only 14 per cent of those receiving rimantadine and 9 per cent of those receiving amantadine (P<0.001 for either drug vs. placebo). Laboratory-documented influenza occurred in 21 per cent of placebo recipients, 3 per cent of rimantadine recipients, and 2 per cent of amantadine recipients (P<0.001). These findings represent efficacy rates of 85 per cent for rimantadine and 91 per cent for amantadine, as compared with placebo. More recipients of amantadine (13 per cent) than recipients of rimantadine (6 per cent; P<0.05) or placebo (4 per cent; P<0.01) withdrew from the study because of Central-nervous-system side effects. On the basis of this study, rimantadine appears to be the drug of choice for the prophylaxis of influenza A. (N Engl J Med. 1982; 307: 580–4.)
AMANTADINE hydrochloride (1-adamantanamine hydrochloride) was licensed in 1966 for the prophylaxis of infections with influenza A viruses of the H2N2 subtype, and it has subsequently been approved for the prophylaxis of infections with all influenza A subtypes. Despite accumulated evidence of the efficacy of amantadine in the prophylaxis of influenza in human beings,
1
2
3
4
5
6
the drug has received relatively little use for this purpose. In part, this has been a result of continued challenges to the evidence of its efficacy by some workers,
7
as well as concern over its reported side effects, which have varied considerably in frequency from study to . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>7050702</pmid><doi>10.1056/NEJM198209023071002</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1982-09, Vol.307 (10), p.580-584 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_15501400 |
| source | MEDLINE; ProQuest Central UK/Ireland |
| subjects | Adamantane - analogs & derivatives Adolescent Adult Amantadine Amantadine - adverse effects Amantadine - therapeutic use Antimicrobial agents Antiviral drugs Chemotherapy Clinical Trials as Topic Disease prevention Enzymes Family medical history Health surveillance Humans Illnesses Immunoglobulins Infant, Newborn Infections Infectious diseases Influenza Influenza A influenza A virus Influenza A virus - isolation & purification Influenza, Human - epidemiology Influenza, Human - prevention & control Laboratory animals Middle Aged Outbreaks Patient Compliance Prophylaxis Random Allocation Respiratory diseases Rimantadine - adverse effects Rimantadine - therapeutic use Viruses Volunteers |
| title | A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza a Infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T16%3A36%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Controlled%20Trial%20of%20Amantadine%20and%20Rimantadine%20in%20the%20Prophylaxis%20of%20Influenza%20a%20Infection&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Dolin,%20Raphael&rft.date=1982-09-02&rft.volume=307&rft.issue=10&rft.spage=580&rft.epage=584&rft.pages=580-584&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJM198209023071002&rft_dat=%3Cproquest_cross%3E15501400%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1872277871&rft_id=info:pmid/7050702&rfr_iscdi=true |